Highlights Johnson & Johnson Lima

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 05:30:00 29/06/2024 am IST			5-day change	1st Jan Change
146.4 ^USD	-0.03%		-0.46%	-4.75%

28/06	Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	MT
28/06	J&J Unit's Rybrevant Combo Gets EU Approval	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	28/06	MT
J&J Unit's Rybrevant Combo Gets EU Approval	28/06	MT
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	28/06	CI
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	28/06	MT
Dealmakers optimistic on global M&A prospects despite sluggish growth	28/06	RE
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06	RE
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06	RE
J&J: 50M pupils helped through 'Sight for Kids' program	24/06	CF
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06	MT
Johnson & Johnson: acquisition of Proteologix completed	21/06	CF
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	21/06	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	21/06	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	21/06	CI
J&J: launches open, secure digital ecosystem	20/06	CF
J&J: promising results in Crohn's disease	20/06	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	20/06	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	20/06	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST